Eurofins Scientific SE · EURONEXT:ERF

Eurofins Scientific — 9M 2022 Earnings Presentation

11 slides from Eurofins Scientific's earnings presentation, Oct 18, 2022

  1. Slide 1: 9M 2022 Trading Update

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  2. Slide 2: Disclaimer

    Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific SE and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on in

  3. Slide 3: Key financial and operational highlights

    Key financial and operational highlights Reported Revenues Key Highlights • Record-high 9M 2022 revenues driven by steady organic growth and acquisitions that more than compensated for the year-on-year decrease in revenues from COVID-19 testing and reagents of €5,033m +2.7% approximately €500m vs. 9

  4. Slide 4: Significant scientific advances to monitor and improve health

    Significant scientific advances to monitor and improve health Outside of COVID-19 testing, Eurofins remains an important contributor to improving human health: o Eurofins Belgium NV has begun carrying out the largest European biomonitoring project for PFAS in blood in Antwerp, commissioned by the Ag

  5. Slide 5: TruGraf Liver, the first and only gene expression diagnostic test

    TruGraf Liver, the first and only gene expression diagnostic test to optimise immunosuppression in liver transplant recipients The liver transplant market Current Patient Care liver transplants 1 >10k performed annually in the US $1M cost per liver transplant • Liver function tests • Gene expression

  6. Slide 6: Eurofins Sustainability Solutions Launched

    Eurofins Sustainability Solutions Launched Eurofins Sustainability Solutions bring together a wide range of Eurofins companies’ sustainability offerings in one place and enable global customers to benefit from the Eurofins network’s market leading solutions to contribute to product and enterprise su

  7. Slide 7: Outlook

    Outlook Eurofins is confirming its objectives for 2022 and plans to update its objectives for 2023 and 2024 when publishing its FY 2022 results on 22 February 2023. By then, the potential impacts of the war in Ukraine, supply chain disruptions, ongoing/permanent COVID-19 testing, inflation and forei

  8. Slide 8: Q&A

    Q&A CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 8

  9. Slide 9: Appendix

    Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 9

  10. Slide 10: Breakdown of Revenue by Operating Segment

    Breakdown of Revenue by Operating Segment €m 9M 2022 As % of total 9M 2021 As % of total Growth % Europe 2,651 52.7% 2,939 60.0% -9.8% North America 1,851 36.8% 1,557 31.8% 18.9% Rest of the World 531 10.6% 406 8.3% 30.7% Total 5,033 100.0% 4,902 100.0% 2.7% €m Q3 2022 As % of total Q3 2021 As % of

  11. Slide 11: Definitions / Alternative Performance Measures (APMs)

    Definitions / Alternative Performance Measures (APMs) Eurofins is providing in the consolidated financial statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results – reflect the ongoing performance of the mature and re

Eurofins Scientific — 9M 2022 Earnings Presentation on 6ix